10-Q 1 d10q.txt FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Quarter Ended April 30, 2002 Commission File Number 1-9579 Ecogen Inc. (Exact name of registrant as specified in its charter) Delaware 22-2487948 -------- ---------- (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 2000 W. Cabot Boulevard #170, Langhorne, Pennsylvania 19047 ----------------------------------------------------- ----- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (2l5) 757-l590 -------------- Indicate by check mark whether the registrant (l) has filed all reports required to be filed by Section l3 or l5 (d) of the Securities Exchange Act of l934 during the preceding l2 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes X No___. --- Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: Class Outstanding at June 4, 2002 ----- --------------------------- Common Stock, $.01 par value 41,790,094 ECOGEN INC. INDEX

ECOGEN INC, AND SUBSIDIARIES UNAUDITED CONSOLIDATED CONDENSED BALANCE SHEETS

See Accompanying Notes to Unaudited Consolidated Condensed Financial Statements. 1 ECOGEN INC, AND SUBSIDIARIES UNAUDITED CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

See Accompanying Notes to Unaudited Consolidated Condensed Financial Statements. 2 ECOGEN INC. AND SUBSIDIARIES UNAUDITED CONSOLIDATED CONDENSED STATEMENT OF STOCKHOLDERS' (DEFICIT) Six months ended April 30, 2002

See Accompanying Notes To Unaudited Consolidated Condensed Financial Statements. 3 ECOGEN INC. AND SUBSIDIARIES UNAUDITED CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(Continued) ECOGEN INC. AND SUBSIDIARIES UNAUDITED CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS, CONTINUED

During the first half of fiscal 2001, the Company transferred ownership of certain fixed assets to a contract manufacturer in exchanged for $250,000 in credits to be applied toward future costs of production at that facility. Any unused balance is payable in cash at the end of two years. During the first half of fiscal 2002 and 2001, the Company issued 26,874,353 and 734,988 shares of common stock, respectively, upon conversion of the Company's preferred stock. In connection with the conversion, the Company issued 163,935 and 51,289 shares of its common stock, respectively in payment of dividends. See Accompanying Notes to Unaudited Consolidated Condensed Financial Statements. 5 ECOGEN INC. AND SUBSIDIARIES Notes to Unaudited Consolidated Condensed Financial Statements April 30, 2002 and 2001 (1) Basis of Presentation and Summary of Significant Accounting Policies Organization and Basis of Presentation: The consolidated condensed financial statements include the accounts of Ecogen Inc. ("Ecogen" or the "Company") and its wholly-owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated condensed financial statements include all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. The consolidated condensed financial statements have been prepared in accordance with the requirements for Form 10-Q and, therefore, do not include all disclosures of financial information required by generally accepted accounting principles. These consolidated condensed financial statements should be read in conjunction with the Company's October 31, 2001 consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K. The results of operations for the interim period ended April 30, 2002 are not necessarily indicative of the operating results for the full year. Operations: The Company is a biotechnology company specializing in the development and marketing of environmentally compatible products for the control of pests in agricultural and related markets. The Company has not achieved profitable operations for any of its fiscal years and there is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. Further, the Company's future operations are dependent, among other things, on the success of the Company's commercialization efforts and market acceptance of the Company's products and technology. Net Loss Per Common Share: Basic loss per share is based on net loss allocable to common stockholders for the relevant period, divided by the weighted average number of common shares outstanding during the period. Diluted loss per share is based on net loss allocable to common stockholders for the relevant period divided by common shares outstanding and other potential common shares if they are dilutive. Because the Company reported a net loss per share, there is no difference between the Company's basic and diluted net loss per share calculations, since all potential common shares were anti-dilutive. (Continued) 6 ECOGEN INC. AND SUBSIDIARIES Notes to Unaudited Consolidated Condensed Financial Statements, Continued (2) Liquidity The Company has reported net losses allocable to common stockholders of ($1,198,000) and ($2,547,000) for the six-month periods ended April 30, 2002, and 2001, respectively. The loss from inception in 1983 to April 30, 2002 amounts to ($139,913,000). Further, the Company has a working capital deficit, a stockholders' deficit and limited liquid resources. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of reported asset amounts or the amount or classification of liabilities, which might result from the outcome of this uncertainty. The Company's continued operations will depend on its ability to raise additional funds. To date, the Company has not generated positive cash flow from operations. Since its inception, the Company financed its working capital needs primarily through private and public offerings of equity and debt securities, revenues from research and development alliances and product sales. The Company secured a $1,500,000 term loan from a bank that is controlled by a principal of the Company's majority stockholder ("Term Loan") and notes from a corporation affiliated with the majority stockholder ("Notes") that are due on June 23, 2002. As of April 30, 2002, the Company had borrowed $1,255,500 under the Notes. Subsequent to April 30, 2002, the Company borrowed an additional $250,000 under Notes. At the time of entering into the additional loans, the terms of the Notes were amended to include all of the Company's assets as security for the Notes. On May 6, 2002, the Company signed an Asset Purchase Agreement with Certis USA, LLC ("Certis"), an indirect subsidiary of Mitsui & Co., for the sale of certain assets relating to the Company's sprayable Bt bio-pesticide business and the Company's insecticidal nematode business including, but not limited to, the Company's CryMax , Lepinox, Condor, Condor G, Raven, Bti technicals and HB nematode product lines. The transaction excludes the Bt CellCap products acquired from Mycogen Corporation and the Company's agreements with the Monsanto Company relating to the royalty arrangements for transgenic plants. The assets to be sold include all technology and know-how related to the business, including strain libraries for bio-pesticide uses, product registration, trademarks, patents or licenses and certain inventory and fixed assets. Upon the closing of the transaction, the Company will receive cash purchase price of $4,015,000 (net of approximately $100,000 in out of pocket expenses) subject to certain adjustments. The closing of the transaction is subject to certain conditions including obtaining approval of the Company's stockholders. Further, as a condition to the closing of the transaction, the Company is required to pay certain of its liabilities associated with the assets to be sold including the payment of the Term Loan and the Notes to remove the liens on such assets (Continued) 7 ECOGEN INC. AND SUBSIDIARIES Notes to Unaudited Consolidated Condensed Financial Statements, Continued (2) Liquidity (con't) and approximately $100,000 in accounts payable and accrued expenses. At May 31, 2002, the aggregate amounts due under the Term Loan and Notes, including accrued interest were $3,372,000. After the payments of the Company's liabilities as described above, the net proceeds from the sale of approximately $543,000 will not be sufficient for the Company to pay its existing liabilities. The Company will need to continue to pursue the raising of additional funds and other strategic initiatives including the sale of all or certain other assets to improve its working capital position. The Company also has taken a number of steps to conserve cash, including significant personnel reductions and related costs and the curtailment of all manufacturing until it is able to sell assets. The Company needs to sell other assets or obtain financing to provide the necessary cash resources to repay the outstanding balances under it's accounts payable and fund operations. At the present time, the Company is not pursuing any long-term financing. Further the Company needs to continue to obtain short-term funding while it negotiates potential sales. At this time the Company is unable to predict whether it will be successful in its efforts. If the Company is not successful in obtaining additional funding or selling assets, the Company will not be able to continue as a going concern. Over the long-term, the Company's liquidity is dependent on market acceptance of its products and technology, including products, if any, commercialized by Monsanto Company utilizing the Company's technology. (3) Loan Agreements The Company has a secured term loan ("Term Loan") with a principal balance of $1,500,000 with a financial institution that is controlled by a principal of the Company's majority stockholder. The Term Loan including unpaid interest is due in June 2002. The loan bears interest at prime plus 2%. The Company's assets collateralize the loan. A corporation affiliated with the majority stockholder guarantees the loan. In connection with the guarantee, the corporation was issued a five-year warrant to purchase 200,000 shares of the Company's common stock at $1.25 per share. The value of such warrants of $183,556 has been recorded as deferred debt expense and was amortized as interest expense over the life of the loan. At April 30, 2002, a corporation affiliated with the Company's majority stockholder had loaned the Company an aggregate of $1,255,000 pursuant to promissory notes ("Notes") that are due June 30, 2002, bear interest at 12%, and are secured by an interest in any success fees received under the Company's agreement with Monsanto Company. Subsequent to April 30, 2002, such corporation loaned the Company an additional $250,000 pursuant to the Notes under the same terms as indicated previously. At the time of entering into the additional loans, the terms of the Notes were amended to include all of the Company's assets as security for the Notes. Under the agreement with Certis, as described in note 5, the balances due under the Term Loan and the Notes plus accrued interest are required to be paid concurrent with the closing of the sale of assets in order to remove the lien on the assets to be sold. (Continued) 8 ECOGEN INC. AND SUBSIDIARIES Notes to Unaudited Consolidated Condensed Financial Statements, Continued (4) Stockholders' Equity In November 2001, 11,500 shares of the Series 1998 C Preferred Stock were converted into 25,000,000 shares of the Company's common stock in accordance with the terms of the preferred stock. As a result of the conversion, the holder of the preferred stock owns 62% of the Company's outstanding common shares. After the conversion, 20,854 shares of the Series 1998 C Convertible Preferred Stock remain outstanding. During the six month period ended April 30, 2002, the Company issued 2,183,313 shares of its common stock in exchange for 725 shares of the Company's Series 2000-A 7% Convertible Preferred Stock. The Company also issued 163,935 shares of its common stock in payment of cumulative dividends at the time of conversion. Subsequent to April 30, 2002, the Board of Directors of the Company approved a 1 for 10 reverse stock split, subject to obtaining stockholder approval. (5) Sale of Assets On May 6, 2002, the Company signed an Asset Purchase Agreement with Certis, an indirect subsidiary of Mitsui & Co., for the sale of certain assets relating to the Company's sprayable Bt bio-pesticide business and the Company's insecticidal nematode business including, but not limited to, the Company's CryMax , Lepinox, Condor, Condor G, Raven, Bti technicals and HB nematode product lines. The transaction excludes the Bt CellCap products acquired from Mycogen Corporation and the Company's agreements with the Monsanto Company relating to the royalty arrangements for transgenic plants. The assets to be sold include all technology and know-how related to the business, including strain libraries for bio-pesticide uses, product registration, trademarks, patents or licenses and certain inventory and fixed assets. Upon the closing of the transaction, the Company will receive cash purchase price of $4,015,000 (net of out of pocket expenses of approximately $100,000) subject to certain adjustments. The closing of the transaction is subject to certain conditions including obtaining approval of the Company's stockholders. Further, as a condition to the closing of the transaction, the Company is required to pay certain of its liabilities associated with the assets to be sold including the payment of the Term Loan and the Notes to remove the liens on such assets and approximately $100,000 in accounts payable and accrued expenses. At May 31, 2002, the aggregate amounts due under the Term Loan and Notes, including accrued interest were $3,372,000. A summary of assets to be sold is as follows: Inventory $ 64,000 Other current assets 65,000 Intangibles and other assets 747,000 ----------- 876,000 Net Proceeds 4,015,000 ----------- Gain on sale of assets $ 3,139,000 =========== (Continued) 9 ECOGEN INC. AND SUBSIDIARIES Notes to Unaudited Consolidated Condensed Financial Statements, Continued (5) Sale of Assets, con't The unaudited pro forma consolidated balance sheet presented is based upon the Company's historical consolidated balance sheet at April 30, 2002, after giving effect to (i) the sale of assets as described above and the receipt of estimated $4,015,000 cash purchase price from the sale, (ii) the payment of $1,700,000 for amounts due under the Term Loan and $1,400,000 for the amounts due under the Notes including accrued interest at April 30, 2001 as described previously in note 3 and (iii) the payment of $100,000 in accounts payable and accrued expenses. 10 ECOGEN INC. AND SUBSIDIARIES Management's Discussion and Analysis of Results of Operations and Financial Condition Three Months and Six Months Ended April 30, 2002 and 2001 SIX MONTHS ENDED APRIL 30, 2002 AND 2001 Revenues Net product sales were $421,000 and $1,598,000 for the first six months of fiscal 2002 and 2001, respectively, representing a decrease of 74%. Sales of the Company's Bt product line, representing 94% of Company's product sales in the first six months of fiscal 2002, decreased 73%. The decrease in sales was due principally to the Company's lack of financial resources including its inability to fund production and secure additional finished goods from Dow Agrosciences LLC. In January 2002, Dow terminated the Supply Agreement as a result of Ecogen's alleged failure to remedy its breaches under the agreement. As a result of the termination of the Supply Agreement, the Company currently is unable to sell any products acquired from Mycogen. Since Dow owns the manufacturing process, the Company is unable to contract with a third party for the manufacture of these products. Although the Company is in discussions with Dow to resolve the situation, there is no assurance that the Company will be successful. Due to the termination of the Dow supply agreement, the sale of assets to Certis and the Company's lack of liquidity, sales are expected to continue to decline. The Company's source of product sales is dependent upon its limited amount of inventory. Biofungicide product sales, which represented 6% of product sales in fiscal 2002, decreased from 9% of product sales in the year-ago period. The Company discontinued marketing its biofungicide products in fiscal 2001. The limited product sales represent the sale of available finished products. Contract research revenues decreased to zero from $.2 million due to grants funded in fiscal 2001. The Company has discontinued all research and development efforts in fiscal 2002. Costs and Expenses Cost of products sold decreased 85% in the first six months of fiscal 2002 compared to the same period in fiscal 2001. Gross margins on product sales were 48% for fiscal 2002 and 7% in fiscal 2001. The higher gross margins in fiscal 2002 were principally due to sales of certain products that had been fully reserved and therefore had no costs associated with such sales. Total operating expenses were $979,000 in the first six months of fiscal 2002, compared to $2,402,000 in the same period in fiscal 2001, a decrease of 59% due to cost reduction measures implemented by the Company in fiscal 2002 and 2001 to conserve cash, including significant personnel reductions. There were no research and development expenses in fiscal 2002 due to the Company's decision to curtail all research and development due to its limited resources. Research and development expenses in the first half of fiscal 2001 were $482,000. The remaining decrease is related to selling general and administrative expenses, which the Company expects to continue to decrease. 11 Operating loss was ($778,000) in the first six months of fiscal 2002 compared to ($2,118,000) in 2001. The decrease was due principally to lower operating expenses in fiscal 2002. Total other expense, increased in the first six months of fiscal 2002 compared to the same period in fiscal 2001 due primarily to $155,000 in gains on the sales of assets in fiscal 2001. Net Loss Net loss allocable to common stockholders for the six months ended April 30, 2002 were ($1,198,000), decreased when compared to a net loss allocable to common stockholders of ($2,547,000) for the same period in fiscal 2001 substantially as a result of lower expenses. Basic and diluted net loss per share for the six months ended April 30, 2002 was ($.03), compared to net loss per share of ($.18) in fiscal 2001 on weighted average shares outstanding of 38.9 million and 13.8 million in the first six months of fiscal 2002 and 2001, respectively. Net loss allocable to common stockholders included preferred stock dividends of $185,000 and $262,000 in fiscal 2002 and 2001 respectively. THREE MONTHS ENDED April 30, 2002 AND 2001 Revenues Net product sales decreased $650,000 or 80% in the three month period ended April 30, 2002 when compared to the same period in fiscal 2001 principally due to lower volume of the Company's Bt products. The Company has discontinued its biofungicide business. The decrease in Bt product sales was due principally to the Company's lack of financial resources including its inability to fund production and secure additional finished goods from Dow Agrosciences LLC. In January 2002, Dow terminated the Supply Agreement as a result of Ecogen's alleged failure to remedy its breaches under the agreement. As a result of the termination of the Supply Agreement, the Company currently is unable to sell any products acquired from Mycogen. Since Dow owns the manufacturing process, the Company is unable to contract with a third party for the manufacture of these products. Although the Company is in discussions with Dow to resolve the situation, there is no assurance that the Company will be successful. Due to the termination of the Dow supply agreement, the sale of assets to Certis and the Company's lack of liquidity, sales are expected to continue to decline. The Company's source of product sales is dependent upon its limited amount of inventory. Costs and Expenses Cost of products sold was $8,000 in the second quarter of fiscal 2002 representing a gross margin on product sales of 95%. The higher margins in the second quarter of fiscal 2002 were due principally to sales of certain finished products that had no costs as a result of a previously recorded reserve against the carrying amount of such inventory. Total operating expenses consisting of research and development and selling, general and administrative expenses were $489,000 in the second quarter of fiscal 2002, compared to $1,281,000 in the same period in fiscal 2001, a decrease of 62% due to cost reduction measures implemented by the Company to conserve 12 cash, including significant personnel reductions and related costs and a reduction in outside services. Further cost reductions have been implemented in operating expenses subsequent to the end of the second quarter of fiscal 2002. There was no research and development activity in fiscal 2002 The operating loss improved from ($1,104,000) in the second quarter of fiscal 2001 to ($341,000) in the second quarter of fiscal 2002. The improvement was primarily due to the decrease in operating expenses. Net Loss Net loss allocable to common stockholders for the three months ended April 30, 2002 was ($560,000), compared to a net loss allocable to common stockholders of ($1,307,000) for the same period in fiscal 2001. Basic and diluted net loss per share for the three months ended April 30, 2002 was ($0.01), compared to net loss per share of ($0.09) in the second quarter of fiscal 2001 on weighted average shares outstanding of 41.4 million and 14.2 million in the second quarter of fiscal 2002 and 2001, respectively. Net loss allocable to common stockholders included preferred stock dividends of $87,000 and $127,000 in the second quarter of fiscal 2002 and 2001, respectively. Seasonality of Business The bulk of the Company's current products are presently marketed for agricultural applications in the northern hemisphere, where the growing season generally runs from spring through fall. Because of the seasonal nature of its business, the Company's product revenues are likely to be concentrated in the fiscal quarters prior to and during a particular growing season, which may result in substantial variations in quarter-to-quarter financial results. Product sales from year-to-year are also affected by unusual weather conditions, such as droughts or floods, and the level of insect pressure in grower areas. In addition, commercial introduction of the Company's new products is contingent on, among other factors, completion of field testing and receipt of required regulatory approvals. Unusual weather conditions during field tests or failure to receive regulatory approvals prior to the growing season may require additional field tests in subsequent growing seasons, with resulting delays in product development and commercialization. Liquidity and Capital Resources At April 30, 2002, the Company had cash on hand of $2,525. The Company funded its operating loss in the first half of fiscal 2002 primarily through decreases in inventory and accounts receivable, limited sale of assets and proceeds from the Notes. At April 30, 2002, current liabilities were $8,307,000 and current assets were $637,000, resulting in a working capital deficit of $7,670,000. Current liabilities increased $801,000 from October 31, 2001 due primarily to non-cash interest and dividends and additional borrowings under the Notes. At April 30, 2002, the Company had $3,187,000 in accounts payable. Certain of these creditors have initiated legal and other action for collection of amounts overdue. Included in current liabilities at April 30, 2002 are net borrowings under debt facilities of $2,755,000. During the six month period ended April 30, 2002, the Company issued 2,183,313 shares of its common stock in exchange for 725 shares of the Company's Series 2000-A 7% Convertible Preferred Stock. The Company also issued 163,935 shares of its common stock in payment of cumulative dividends at the time of conversion. 13 During fiscal 2000, the Company obtained a $1.500,000 variable rate secured term loan with the Berkshire Bank, a financial institution controlled by a principal of United Equities (Commodities) Corporation, the Company's current majority stockholder. The maturity date of the Term Loan was extended to June 2002 for all principal, interest and penalty payments. Further, a corporation affiliated with the majority stockholder loaned the Company an aggregate of $1,255,000 through April 30, 2002 pursuant to promissory notes ("the Notes") which are due in June 2002 and bear interest at 12%. Subsequent to April 30, 2002, the Company borrowed an additional $250,000 pursuant to the Notes. On September 11, 2000, the Company's common stock was delisted from the Nasdaq National Market ("NNM") as a result of the Company's failure to meet the NNM's net tangible assets listing requirement. As a result, dividends on the Company's Series 2000-A and Series 1998-C Convertible Preferred Stock are payable in cash, beginning with the quarterly dividend payment date of September 30, 2000 and the semiannual dividend payment date of December 31, 2000, respectively. The Company no longer has the option to pay such dividends in stock. Under Delaware Law, the Company is precluded from paying cash dividends due to its deficit in stockholders' equity and therefore is in default of its preferred stock. The Company's continued operations will depend on its ability to raise additional funds. To date, the Company has not generated positive cash flow from operations. Since its inception, the Company financed its working capital needs primarily through private and public offerings of equity and debt securities, revenues from research and development alliances and product sales. The Company secured a $1,500,000 Term Loan from a bank that is controlled by a principal of the Company's majority stockholder and Notes aggregating $1,255,000 at April 30, 2002 from a corporation affiliated with the majority stockholder that are due on June 23, 2002. At May 31, 2002, the aggregate amounts due under the Term Loan and Notes, including accrued interest were $3,372,000. On May 6, 2002, Ecogen Inc. (the "Company") signed an Asset Purchase Agreement with Certis USA, LLC ("Certis"), an indirect subsidiary of Mitsui & Co., for the sale of certain assets relating to the Company's sprayable Bt bio-pesticide business and the Company's insecticidal nematode business including, but not limited to, the Company's CryMax, Lepinox, Condor, Condor G, Raven, Bti technicals and HB nematode product lines. The transaction excludes the Bt CellCap products acquired from Mycogen Corporation and the Company's agreements with the Monsanto Company relating to the royalty arrangements for transgenic plants. The assets to be sold include all technology and know-how related to the business, including strain libraries for bio-pesticide uses, product registration, trademarks, patents or licenses and certain inventory and fixed assets. Upon the closing of the transaction, the Company will receive estimated cash purchase price of $4,015,000. The closing of the transaction is subject to certain conditions including obtaining approval of the Company's stockholders. Further, as a condition to the closing of the transaction, the Company is required to pay certain of its liabilities associated with the assets to be sold including the payment of the Term Loan and the Notes to remove the liens on such assets and approximately $100,000 in accounts payable and accrued expenses. At May 16, 2002, the aggregate amounts due under the Term Loan and Notes, including accrued interest were $3,372,000. After the payments of the Company's liabilities as described above, the net proceeds from the sale of approximately $543,000 will not be sufficient for the Company to pay its existing liabilities. The Company will need to continue to pursue the raising of additional funds and other strategic initiatives including the sale of all or certain other assets to improve its working capital position. The 14 Company also has taken a number of steps to conserve cash, including significant personnel reductions and related costs and the curtailment of all manufacturing until it is able to sell assets. The Company needs to sell other assets or obtain financing to provide the necessary cash resources to repay the outstanding balances under it's accounts payable and fund operations. At the present time, the Company is not pursuing any long-term financing. Further the Company needs to continue to obtain short-term funding while it negotiates potential sales. At this time the Company is unable to predict whether it will be successful in its efforts. If the Company is not successful in obtaining additional funding or selling assets, the Company will not be able to continue as a going concern. Over the long-term, the Company's liquidity is dependent on market acceptance of its products and technology including products, if any, commercialized by the Monsanto Company utilizing the Company's technology. The report of our independent auditors on the Company's consolidated financial statements for the years ended October 31, 2001 and 2000 included an explanatory paragraph which stated that the recurring losses from operations, working capital deficiency, net capital deficiency and limited liquid resources raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Recently Issued Accounting Standards In June 1998, the Financial Accounting Standard Board issued Statement No. 133 "Accounting for Derivative Instruments and Hedging Activities" (FAS 133"). FAS 133 was required to be adopted for the fiscal year beginning November 1, 2000. However, because it does not use derivatives, the adoption of FAS 133 did not effect the results of operations or the financial position of the Company. In December 1999, the staff of the Securities and Exchange Commission issued Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements (SAB 101). SAB 101 summarizes certain of the staff's views in applying generally accepted accounting principles to revenue recognition in financial statements. SAB 101 required the Company to follow its guidance no later than its fiscal year beginning November 1, 2000 through a cumulative effect of a change in accounting principle. The adoption of this standard did not have a material impact on our financial statements. In April 2000, the Financial Accounting Standard Board Interpretation No. 44, "Accounting for Certain Transactions Involving Stock Compensation-An Interpretation of APB Opinion No. 25" ("FIN 44") was issued. Fin 44 clarifies the application of APB No. 25 for certain issues. Among other issues, FIN 44 clarifies the definition of employee for purposes of applying APB no. 25, the criteria for determining whether a plan qualifies as non-compensatory plan, the accounting consequences of various modifications to the term of a previously fixed stock option or award, and the accounting for an exchange of stock compensation awards in a business combination. Fin 44 became effective July 1, 2000. The adoption of FIN 44 did not have a significant effect on the Company's financial position or results of operations. 15 In June 2001, the Financial Accounting Standards Board issued Statement No. 141, "Accounting for Business Combinations (FAS 141) and Statement No. 142, Accounting for Goodwill and Intangible Assets (FAS 142). FAS 141 and 142 change the method of accounting for mergers and acquisitions. Under FAS 141 pooling-of-interest accounting may no longer be used. Under FAS 142 purchased goodwill will be subject to impairment reviews rather then amortizing goodwill over a specific period. The effective date for FAS 141 is for transactions entered into after June 30, 2001. FAS 142 will be effective for fiscal years beginning after December 31, 2001. Earlier application is permitted, however FAS 142 must be adopted at the beginning of a fiscal year. Adoption of FAS 142 is not expected to have a material impact on the Company's consolidated financial statements. Forward-Looking Statements All statements contained in this management's discussion and analysis of financial condition and results of operations other than statements of historical information, are forward-looking statements. Forward-looking statements include statements containing plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements which are other than historical facts. Although the Company believes that its expectations are based on reasonable assumptions, the Company operates in a high technology, emerging market environment that involves significant risks and uncertainties which may cause actual results to vary from such forward-looking statements and to vary significantly from reporting period to reporting period. These risks include among others, those listed in "Factors That May Affect Future Results", in the Company's Annual Report on Form 10K for the year ended October 31, 2001, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update the results discussed herein as a result of changes in risks or operating results. 16 PART II - OTHER INFORMATION Item 6 Exhibits and reports in Form 8-K (a) Exhibits Exhibit No. Description 3.1 Restated Certificate of Incorporation of Ecogen Inc. (Form 10-Q for fiscal quarter ended January 31, 1996)* 3.2 By-laws of Ecogen Inc., as amended (Form S-1 Registration Statement, File No. 33-14119)* 3.3 Certificate of Designations, Preferences and Rights of Series 1998-A Convertible Preferred Stock (Form 10-Q for fiscal quarter ended April 30, 1998)* 3.4 Certificate of Designations, Preferences and Rights of Series 1998-C Convertible Preferred Stock (Form 8-K, dated September 2, 1998)* 3.5 Certificate of Designations, Preferences and Rights of Series 1999-A Convertible Preferred Stock (Form 10-Q, for fiscal quarter ended April 30, 1999)* 3.6 Certificate of Designations, Preferences and Rights of Series 2000-A Convertible Preferred Stock (Form 10-K, for fiscal year ended October 31, 1999)* 10.153 Asset Purchase and License Agreement between Ecogen Inc. and Mycogen Corporation dated as of February 15, 2000 (Current Report on Form 8-K dated March 1, 2000)* 10.154 Stockholders Agreement between Ecogen Inc. and Mycogen Corporation dated February 15, 2000 (Current Report on Form 8-K dated March 1, 2000)* 10.155 Purchase and Sale Agreement between Ecogen Inc. and Dow AgroSciences LLC dated as of February 15, 2000 (Current Report on Form 8-K dated March 1, 2000)* 10.156 Convertible Preferred Stock Purchase Agreement between Ecogen Inc. and Amro International, S.A., Aspen International, Ltd. and Markham Holdings Limited dated as of February 14, 2000 (Form 10-Q for the fiscal quarter ended January 31, 2000)* 10.157 Registration Rights Agreement between Ecogen Inc. and Amro International, S.A., Aspen International, Ltd. and Markham Holdings Limited dated as of February 14, 2000 (Form 10-Q for the fiscal quarter ended January 31, 2000)* _________________________ * These items are hereby incorporated by reference from the exhibits of the filing or report indicated and are made part of this Report. 17 10.158 Warrant Agreement between Ecogen Inc. and Amro International, S.A. dated February 14, 2000 (Form 10-Q for the fiscal quarter ended January 31, 2000)* 10.159 Warrant Agreement between Ecogen Inc. and Aspen International, Ltd. dated February 14, 2000 (Form 10-Q for the fiscal quarter ended January 31, 2000)* 10.160 Warrant Agreement between Ecogen Inc. and Markham Holdings Limited dated as of February 14, 2000 (Form 10-Q for the fiscal quarter ended January 31, 2000)* 10.161 Form of Demand Promissory Note to Momar Corporation (Form 10-K for the fiscal year ended October 31, 2000) * 10.162 Letter Agreement between Ecogen Inc. and Momar Corporation dated May 16, 2002 (Form 10-K for the fiscal year ended October 31, 2001)* 10.163 Asset Purchase Agreement by and among Certis USA L.L.C., Ecogen Inc., Ecogen-Bio Inc. and Ecogen Technologies Incorporated dated May 6, 2002. 10.164 Pre-closing Business Arrangement Agreement by and among Certis USA L.L.C., Ecogen Inc., Ecogen-Bio Inc. and Ecogen Technologies Incorporated dated May 6, 2002. 10.165 List of omitted schedules/exhibits to Asset Purchase Agreement by and among Certis USA L.L.C., Ecogen Inc., Ecogen-Bio Inc. and Ecogen Technologies Incorporated dated May 6, 2002. (b) Current Reports on Form 8-K None ________________________ * These items are hereby incorporated by reference from the exhibits of the filing or report indicated and are made part of this Report. 18 Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: June 7, 2002 ECOGEN INC. By: /s/ James P. Reilly, Jr ------------------------------ James P. Reilly, Jr. Chairman, Chief Executive Officer and Acting Chief Financial and Accounting Officer 19

ECOGEN INC 10-Q